Compass Therapeutics dropped sharply this week while short sellers trimmed positions slightly. Cost to borrow fell to a 30-day low. Options flow turned more cautious. Insider CEO sales continue a multi-quarter pattern.
CMPX closed at $5.03 on April 24, down 3.45% on the day. The stock fell 16.2% over the week and lost 5.6% over the past month. The biotech trades well off recent highs as it approaches a May 6 earnings event.
Short interest stands at 26.1 million shares, or 14.7% of the float. The figure dipped 0.75% over the week and ticked down 0.41% day-over-day. Over the past month short interest rose 14.9%, adding 3.4 million shares. The April 15 FINRA report showed 26.1 million shares short with days to cover at 9.4.
Cost to borrow sits at 0.45%, the lowest level in the past 30 days. CTB peaked at 0.61% on March 24 and has trended lower since early April. The April 3 reading of 0.61% marked the recent high. Utilisation stands at 38.2%, down from a 52-week peak of 45.4%. Utilisation hit 40.8% on March 24 and has oscillated in the 26–40% range since mid-March.
The ORTEX short score is 76.9, near the top of the recent 10-day range.
The put/call ratio closed at 0.32, elevated versus the 20-day mean of 0.15. The current PCR z-score is 1.56, indicating a modest tilt toward put activity. Over the past 52 weeks the PCR ranged from 0.004 to 47.1. The recent five-session stretch shows PCR above 0.31 each day, versus single-digit readings earlier in April.
Consensus sits at buy. Two outperform ratings are on record. Recent coverage includes a March 24 reiteration from Guggenheim's Michael Schmidt at buy with a $12 target. William Blair initiated with an outperform rating on January 5. Cantor Fitzgerald, Citizens, and Canaccord Genuity all initiated coverage in early December with overweight, market outperform, and buy ratings respectively. Citizens and Canaccord set $10 targets. D. Boral Capital has maintained a buy rating with a $30 target across multiple updates.
Benzinga's bull case highlights positive colorectal cancer data and a differentiated safety profile for CTX-8371 across multiple indications. The bear case notes a Q3 2025 net loss widening to $14.3 million from $10.5 million a year earlier, poor tolerability in a failed bispecific trial, and uncertainty around overall survival outcomes.
Earnings yield is –0.083 and moved slightly negative over the past 30 days. The trailing P/E is –12.0. EV/EBITDA stands at –8.9. The biotechnology sector rank is 29th percentile. EPS momentum 30-day and 90-day scores both sit at the 66th percentile. Dividend score is at the 32nd percentile. Short score ranks in the 5th percentile, reflecting an extreme position.
BlackRock added 2.0 million shares in the quarter ended March 31 and now holds 9.4 million shares, or 5.2% of the company. Vanguard added 986,000 shares to reach 8.0 million, or 4.5%. State Street lifted its stake by 1.8 million shares to 4.9 million, or 2.7%. Suvretta Capital increased by 81,000 shares to 14.2 million, or 7.9%. BVF Partners added 3.4 million shares in the December quarter to hold 7.8 million, or 4.3%. Blackstone raised its position by 5.3 million shares to 6.1 million, or 3.4%. Rock Springs Capital trimmed by 548,000 shares. Blackstone Alternative Asset Management cut its stake by 2.9 million shares.
Founder and CEO Thomas Schuetz holds 5.9 million shares, or 3.3%, after adding 201,000 shares as of February 8. Mark Lampert added a 4.7 million share position in late October, representing 2.6% of the company.
CEO Thomas Schuetz sold 36,687 shares on February 6 at $6.52 for $239,000. He sold 46,777 shares on January 9 at $5.35 for $250,000 and 44,025 shares on November 14 at $4.83 for $213,000. In May 2025 Schuetz purchased 10,000 shares at $2.11.
OrbiMed Advisors sold 3.6 million shares in April 2025 at $1.59 for $5.7 million. A general counsel bought 20,000 shares at $1.54 in April 2025. Vice President Neil Lerner bought 20,000 shares at $1.42 the same week.
Net insider activity over the past 90 days shows sales of 127,489 shares for $702,000.
The company reported earnings on March 5 and March 18. Earlier prints occurred on November 10, 2025 and November 5, 2025. Historical post-earnings price moves are not available in this snapshot.
Compass reports earnings on May 6 at 1:30 PM UTC. Pipeline updates on CTX-8371 and CTX-10726 will be in focus. Any commentary on tolerability data, colorectal cancer trial progress, or overall survival endpoints will move the stock. Watch for continued institutional accumulation or further insider sales ahead of the print.
See the live data behind this article on ORTEX.
Open CMPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
